AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more
Market Cap & Net Worth: AMGN (AMGN)
AMGN (NEO:AMGN) has a market capitalization of $195.21K (CA$280.37K) as of March 18, 2026. Listed on the NEO stock exchange, this Canada-based company holds position #1609 globally and #4 in its home market, demonstrating a -2.15% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying AMGN's stock price CA$28.28 by its total outstanding shares 9914 (9.91K).
AMGN Market Cap History: 2025 to 2026
AMGN's market capitalization history from 2025 to 2026. Data shows growth from $171.46K to $195.21K (0.00% CAGR).
AMGN Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how AMGN's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
AMGN's market cap is 0.00 times its annual revenue
0.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
AMGN's market cap is 0.00 times its annual earnings
15.82x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $171.46K | $36.75 Billion | $7.71 Billion | 0.00x | 0.00x |
Competitor Companies of AMGN by Market Capitalization
Companies near AMGN in the global market cap rankings as of March 18, 2026.
Key companies related to AMGN by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
AMGN Historical Marketcap From 2025 to 2026
Between 2025 and today, AMGN's market cap moved from $171.46K to $ 195.21K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CA$195.21K | +13.85% |
| 2025 | CA$171.46K | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of AMGN was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $195.21K USD |
| MoneyControl | $195.21K USD |
| MarketWatch | $195.21K USD |
| marketcap.company | $195.21K USD |
| Reuters | $195.21K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.